Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

@article{Harrington2015ClinicalDO,
  title={Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.},
  author={Kevin J. Harrington and Igor J. Puzanov and Joel Randolph Hecht and Frank Stephen Hodi and Zsolt Roland Szab{\'o} and Swami Murugappan and Howard L. Kaufman},
  journal={Expert review of anticancer therapy},
  year={2015},
  volume={15 12},
  pages={
          1389-403
        }
}
Tumor immunotherapy is emerging as a promising new treatment option for patients with cancer. T-VEC is an intralesional oncolytic virus therapy based on a modified herpes simplex virus type-1. T-VEC selectively targets tumor cells, causing regression in injected lesions and inducing immunologic responses that mediate regression at uninjected/distant sites. In a randomized phase III trial, T-VEC met its primary endpoint of improving the durable response rate vs granulocyte-macrophage colony… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Similar Papers

Loading similar papers…